Who founded 858 Therapeutics, Inc.?

858 Therapeutics, Inc. was founded by Stafford Jeffrey.

Who are 858 Therapeutics, Inc.'s investors?

858 Therapeutics, Inc.'s investors include New Enterprise Associates (NEA), Versant Venture Capital, Versant Ventures.

How much funding has 858 Therapeutics, Inc. raised?

858 Therapeutics, Inc. has disclosed $65.2M raised across 3 rounds.

Where is 858 Therapeutics, Inc. headquartered?

858 Therapeutics, Inc. is headquartered in San Diego, US.

858 Therapeutics, Inc.

San Diego, US · 3 known investors

Find your way into 858 Therapeutics, Inc.

858 Therapeutics is a clinical-stage biotechnology company developing targeted cancer therapies that act on tumor dependencies in DNA damage response (DDR) pathways. Its lead program, ETX-19477, is an oral PARG inhibitor being studied in patients with advanced solid tumors.

Biotech Healthtech

Founders & leadership

Stafford JeffreyinFounder · Chief Executive Officer

James VealExecutive

Katherine Bell-McGuinnExecutive

Joseph LevequeChief Medical Officer

Board

Monal Mehta inBoard directorVenture Partner at Versant Ventures

Ali Behbahani inBoard directorPartner, Co-Head of Healthcare at New Enterprise Associates (NEA)

Clare Ozawa inBoard directorManaging Director at Versant Ventures

Jane HuangBoard director

Investors · 3

New Enterprise Associates (NEA)Menlo Park · $200K – $40Mvia Ali Behbahani · board

Versant Venture CapitalreportedSan Francisco

Versant Venturesreported · 2 sourcesSan Francisco · $250K – $5Mvia Clare Ozawa · board

Reported raises · per SEC filings

Form D private placements

$65.2M disclosed across 3 rounds · 2020–2024

▶$25.2MraisedJul 2024 · 12 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

James VealExecutive Officer
Jane HuangDirector
Monal MehtaDirector
Stafford JeffreyExecutive Officer, Director
Ali BehbahaniDirector
Katherine Bell-McGuinnExecutive Officer
Clare OzawaDirector

Offering amount: $50.4M
Amount sold: $25.2M
First sale: Jun 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$20MraisedMay 2021 · 6 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Carlo RizzutoDirector
Ali BehbahaniDirector
Jeffrey A. StaffordExecutive Officer, Director
James VealExecutive Officer
Clare OzawaDirector

Offering amount: $40M
Amount sold: $20M
First sale: May 2021
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$20.1MraisedMar 2020 · 1 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Clare OzawaDirector
Bradley J. BolzonDirector
James VealExecutive Officer

Offering amount: $37.5M
Amount sold: $20.1M
First sale: Mar 2020
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does 858 Therapeutics, Inc. do?: 858 Therapeutics is a clinical-stage biotechnology company developing targeted cancer therapies that act on tumor dependencies in DNA damage response (DDR) pathways. Its lead program, ETX-19477, is an oral PARG inhibitor being studied in patients with advanced solid tumors.
Who founded 858 Therapeutics, Inc.?: 858 Therapeutics, Inc. was founded by Stafford Jeffrey.
Who are 858 Therapeutics, Inc.'s investors?: 858 Therapeutics, Inc.'s investors include New Enterprise Associates (NEA), Versant Venture Capital, Versant Ventures.
How much funding has 858 Therapeutics, Inc. raised?: 858 Therapeutics, Inc. has disclosed $65.2M raised across 3 rounds.
Where is 858 Therapeutics, Inc. headquartered?: 858 Therapeutics, Inc. is headquartered in San Diego, US.